Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920892 · ClinicalTrials.gov registry record · Phase 2
AFQ056 for Language Learning in Children With FXS
A Phase 2 study, sponsored by Elizabeth Berry-Kravis.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT02920892 is a Phase 2 study that has completed, run by Elizabeth Berry-Kravis. The registered enrollment target is 110 participants.
The verdict
NCT02920892, a Phase 2 study, has completed, sponsored by Elizabeth Berry-Kravis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS).
Interventions
- DRUG Placebo
- OTHER Language Intervention
- DRUG AFQ056
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2017-08-17 |
| Est. Completion | 2022-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02920892
The ClinicalTrials.gov registry entry for NCT02920892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elizabeth Berry-Kravis, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02920892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02920892 about?
NCT02920892 is a clinical study titled "AFQ056 for Language Learning in Children With FXS". The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS).
What is the current status of trial NCT02920892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2017-08-17. Estimated completion is 2022-05-17.
What interventions are being tested in trial NCT02920892?
The interventions under investigation include: Placebo (DRUG), Language Intervention (OTHER), AFQ056 (DRUG).
Who is sponsoring clinical trial NCT02920892?
This trial is sponsored by Elizabeth Berry-Kravis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.